Adult human megakaryocyte-erythroid progenitors are in the CD34+CD38mid fraction

Area of Science:

• Hematology
• Stem Cell Biology
• Molecular Biology

Background:

• Bipotent megakaryocyte/erythroid progenitors (MEPs) are crucial for generating megakaryocyte (Mk) and erythroid (E) lineages.
• Accurate identification and purification of functional MEPs are essential for studying lineage commitment and developing therapies.

Purpose of the Study:

• To develop a novel dual-detection functional assay for identifying and quantifying primary human MEPs.
• To establish effective purification strategies for MEPs and lineage-committed Mk and E progenitors.
• To investigate the role of MYB in the Mk-E lineage fate decision of MEPs.

Main Methods:

• Development of a dual-detection in vitro colony-forming unit (CFU) assay (CFU-Mk/E) for single-cell analysis.
• Utilizing fluorescence-activated cell sorting (FACS) to purify specific cell populations based on surface markers.
• Employing short hairpin RNA (shRNA) to knockdown MYB expression in MEPs for functional studies.

Main Results:

• A novel purification strategy identified the Lin(-)CD34(+)CD38(mid)CD45RA(-)FLT3(-)MPL(+)CD36(-)CD41(-) population as highly enriched for bipotent MEPs.
• Purification strategies were established for lineage-committed Mk progenitors (CFU-Mk) and E progenitors (BFU-E).
• MYB knockdown in MEPs significantly promoted commitment to the megakaryocyte lineage, highlighting MYB's role in lineage fate determination.

Conclusions:

• The novel CFU-Mk/E assay and purification strategies enable precise identification and isolation of human MEPs.
• Differential MYB expression is implicated in the Mk-E lineage commitment decision.
• These findings support mechanistic studies of MEP lineage commitment and offer potential for improved cell expansion and therapeutic strategies for hematologic diseases.